B. Wynne's Profile

Role	Title	Level	Year	L/R
🐜	Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. 14 auth. S. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, A. Eberhard, F. Gutiérrez, L. Hocqueloux, F. Maggiolo, U. Sandkovsky, C. Granier, ... K. Pappa, B. Wynne, S. Min, G. Nichols	9	2013	9 🐜
🐜	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies 14 auth. J. Llibre, C. Hung, C. Brinson, F. Castelli, P. Girard, L. Kahl, Elizabeth A Blair, Kostas Angelis, B. Wynne, Kati Vandermeulen, ... M. Underwood, Kim Smith, M. Gartland, M. Aboud	8	2018	8 🐜
🐜	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 209 auth. P. Cahn, J. S. Madero, J. Arribas, A. Antinori, Roberto Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, Jörg Sievers, C. Man, A. Currie, M. Underwood, A. Tenorio, K. Pappa, ... B. Wynne, Anna Fettiplace, M. Gartland, M. Aboud, Kimberly Smith, L. Cassetti, Daniel David, L. Figueras, M. Losso, G. Lopardo, S. Lupo, N. Porteiro, M. Sánchez, M. Bloch, David Cooper, R. Finlayson, A. Kelleher, Ken Koh, David Lewis, J. McMahon, Richard Moore, N. Roth, M. Shields, S. Wit, E. Florence, J. Goffard, R. Demeester, P. Lacor, B. Vandercam, L. Vandekerckhove, J. Angel, J. Baril, B. Conway, A. Pokomandy, J. Szabo, S. Walmsley, O. Bouchaud, C. Chidiac, P. Delobel, C. Goujard, C. Katlama, J. Molina, G. Pialoux, P. Philibert, J. Bogner, S. Esser, I. Krznaric, C. Lehmann, C. Spinner, H. Stellbrink, C. Stephan, A. Stoehr, E. Barchi, P. Caramello, F. Castelli, A. Cattelan, A. Monforte, A. Biagio, G. Perri, A. Gori, F. Maggiolo, B. Menzaghi, G. Migliorino, C. Mussini, G. Penco, M. Puoti, G. Rizzardini, R. Gulminetti, A. Lazzarin, T. Quirino, L. Sighinolfi, P. Viale, G. A. Tapia, J. A. Villanueva, E. Reyes, A. P. Ríos, Mario Gómez, J. D. Hollander, B. Rijnders, J. Hidalgo, L. H. Vásquez, L. Illescas, A. Olczak, K. Mansinho, P. Pacheco, E. Teófilo, J. D. Cunha, R. E. Castro, R. Serrão, M. Arbune, C. Jianu, A. Oprea, L. Preoțescu, L. Prisăcariu, E. Belonosova, O. Borodkina, O. Chernova, N. Gankina, S. Kizhlo, V. Kulagin, N. Kurina, F. Nagimova, V. Pokrovsky, E. Ryamova, E. Voronin, A. Yakovlev, R. Kaplan, S. H. Lee, Shin-woo Kim, Sang-Il Kim, W. Kim, Antonio Antela López, Jose L Casado Osorio, M. Carracedo, I. Gil, V. E. Pérez, V. Ferrer, L. Force, M. Puerto, M. G. Deltoro, J. Gatell, Miguel A Goenaga Sanchez, A. Cordón, H. Knobel, J. D. Quirós, J. E. L. García, M. Masiá, Marta Montero-Alsonso, Antonio Ocampo Hermida, J. Liaño, J. P. Sogorb, F. P. Ortega, Antonio Rivera Roman, J. Fernandez, R. T. Perea, Jesús García, Pompeyo Viciana Fernández, A. Calmy, C. Hauser, J. Fehr, Shu-Hsing Cheng, W. Ko, Hsi‐Hsun Lin, P. Lu, Y. Tseng, Ning-Chi Wang, W. Wong, Chia-Jui Yang, R. Arduino, P. Benson, M. Berhe, Fritz Bredeek, C. Brinson, Thomas B. Campbell, G. Crofoot, D. Cunningham, E. Dejesus, R. Dretler, J. Eron, K. Fife, C. Fichtenbaum, J. Flamm, D. Goldstein, Samir Gupta, D. Hagins, M. Hoffman-Terry, Dushyantha Jayaweera, Clifford Kinder, D. Klein, Cheryl Mcdonald, A. Mills, R. Nahass, O. Osiyemi, E. Overton, David A Parks, D. Prelutsky, M. Ramgopal, S. Schrader, B. Sha, G. Simon, James Sims, D. Skiest, J. Slim, K. Tashima, B. Thedinger, B. Gazzard, J. Fox, M. Johnson, S. Kegg, S. Khoo, C. Mazhude, C. Orkin, G. Schembri, A. Ustianowski	8	2019	8 🐜
🐜	Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial 15 auth. S. Walmsley, A. Baumgarten, J. Berenguer, F. Felizarta, E. Florence, M. Khuong-Josses, J. Kilby, T. Lutz, D. Podzamczer, J. Portilla, ... N. Roth, Deborah Wong, C. Granier, B. Wynne, K. Pappa	7	2015	7 🐜
🐜	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study 18 auth. J. van Wyk, F. Ajana, F. Bisshop, S. De Wit, O. Osiyemi, J. Portilla Sogorb, J. Routy, C. Wyen, M. Ait‐Khaled, M. Nascimento, ... K. Pappa, Ruolan Wang, Jonathan Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, Kimberly Smith	7	2020	7 🐜
🐜	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials 21 auth. P. Cahn, J. S. Madero, J. Arribas, A. Antinori, Roberto Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, Jörg Sievers, ... C. Man, R. Urbaityte, Daisy J. Brandon, M. Underwood, A. Tenorio, K. Pappa, B. Wynne, M. Gartland, M. Aboud, J. van Wyk, Kimberly Smith	7	2019	7 🐜
🐜	Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study 11 auth. B. Trottier, J. Lake, K. Logue, C. Brinson, L. Santiago, C. Brennan, ... J. Koteff, B. Wynne, J. Hopking, C. Granier, M. Aboud	6	2017	6 🐜
🐜	Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. 17 auth. M. Aboud, C. Orkin, D. Podzamczer, J. Bogner, D. Baker, M. Khuong-Josses, David A Parks, K. Angelis, L. Kahl, Elizabeth A Blair, ... K. Adkison, M. Underwood, J. Matthews, B. Wynne, Kati Vandermeulen, M. Gartland, Kimberly Smith	6	2019	6 🐜
🐜	Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study 11 auth. B. Akil, G. Blick, D. Hagins, M. Ramgopal, G. Richmond, Rafik M Samuel, ... N. Givens, C. Vavro, I. Song, B. Wynne, M. Ait‐Khaled	6	2015	6 🐜
🐢	Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection 21 auth. P. Cahn, J. S. Sierra Madero, J. Arribas, A. Antinori, Roberto Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, Jörg Sievers, ... C. Man, R. Urbaityte, Daisy J. Brandon, M. Underwood, K. Pappa, L. Curtis, Kimberly Smith, M. Gartland, M. Aboud, J. van Wyk, B. Wynne	5	2021	5 🐢
🐜	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. 13 auth. C. Orrell, D. Hagins, E. Belonosova, N. Porteiro, S. Walmsley, V. Falcó, C. Man, A. Aylott, A. Buchanan, B. Wynne, ... C. Vavro, M. Aboud, Kimberly Smith	5	2017	5 🐜